The coexpression of IGF (-I and -II) peptides, corresponding receptors, and IGF binding proteins (IGFBPs) in uterine endometrium suggests that a significant component of IGF action in this tissue is via autocrine or paracrine pathways, or both. The present study examined whether IGF-II and a major uterine-expressed IGF-II binding protein, IGFBP-2, modulate endometrial epithelial cell mitogenesi...

Background. Congenital disorders of glycosylation (CDG) are a group of rare disorders in which glycosylation required for proper protein-protein interactions and protein stability is disrupted, manifesting clinically with multiple system involvement and growth failure. The insulin-like growth factor (IGF) system plays an important role in childhood growth and has been shown to be dysfunctional ...

Materials and Methods: The coadministration of kanamycin and ethacrynic acid was used to deafen the guinea pigs. An absorbable gelatin sponge immersed in recombinant human insulin-like growth factor-1 (rhIGF-1) was placed on the round window membrane of the experimental ear while a sponge containing saline was applied to control ear. Hearing function was assessed by auditory brain stem response...

Mauras, Nelly, Valerie Quarmby, and Duane C. Bloedow. Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins. Am. J. Physiol. 277 (Endocrinol. Metab. 40): E579–E584, 1999.—We investigated the pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) in growth hormone deficiency (GHD). Nine GHD adults [age 25 6 3 (SE) yr] receive...

The aim of this study was to investigate the longitudinal effects of electroacupuncture (EA) on Zusanli (ST36) and Ashi acupoints in promoting skeletal muscle regeneration and inhibiting excessive fibrosis after contusion in rabbits. Sixty rabbits were randomly divided into four groups: normal, contusion, EA, and recombinant human insulin-like growth factor-I (rhIGF-I). An acute skeletal muscle...

We investigated the pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) in growth hormone deficiency (GHD). Nine GHD adults [age 25 ± 3 (SE) yr] received rhIGF-I (60 μg/kg sc) twice, 10 h apart, and blood was sampled over 24 h. IGF-I and free IGF-I concentrations increased, whereas IGF binding protein 3 (IGFBP-3) and acid labile subunit (ALS) were unchanged during treat...

BACKGROUND The growth hormone-IGF (insulin-like growth factor) system plays a central role in hormonal growth regulation. Recombinant human (rh) growth hormone (GH) has been available since the late 1980s for replacement therapy in GH-deficient patients and for the stimulation of growth in patients with short stature of various causes. Growth promotion by GH occurs in part indirectly through th...

The paper by Bright et al. is an effort to authenticate the recently introduced designation of " primary insulin-like growth factor-1 deficiency (IGFD) " and it's treatment with recombinant human insulin-like growth factor-1 (rhIGF-1). The concept of " primary IGFD " is supported by comparison to states of hormone deficiency that occur despite adequate stimulation to the target gland, such as p...